CRL Charles River Laboratories International, Inc.

Healthcare

Price

$304.96

Intrinsic value

$45.70

Buy price

$36.56

Discount

-567.3%

Overvalued [LOW CF reliability]

Live signals (1)

Daily bars as of Oct 8, 2026

UCUptrend ContinuationBullish ↑
A strong bullish bar closing back into a rising 20/50-SMA stack - the uptrend resuming after a pullback to the moving averages.
Fired Oct 8, 2026on the latest daily bar35.8% win rate · 1x profit factor

A pattern is reported for 5 bars after it fires (the sweet-spot fill window), so an older bar count means the entry has had longer to play out - not that the signal is stronger. Win rate and profit factor are the pattern's backtested averages across the S&P 500, not a forecast for this ticker.

DCF walkthrough

Near-term growth (g1)0.33%

Terminal growth (g2)3.50%

Years of g1 growth4

Discount rate9.00%

Margin of safety20.00%

Operating CF: $737,646,000.00
Total debt: $3,034,319,104.00
Cash & STI: $192,024,992.00
Shares out.: 48,021,000

Overvalued [LOW CF reliability]

Intrinsic value$45.68

Buy price (with MOS)$36.55

Current price$304.96

Discount to intrinsic value-567.5%

7-step quality scorecard

ROE quality

LOW

Average ROE: 6.3%
Current ROE: -4.6%
Minimum ROE: -4.6%

Debt quality

MODERATE

Debt / Equity: 0.96x

Moat proxy

WEAK_PROXY

Cash-flow reliability

LOW

Operating CF / Net income: —

Technical chart

Confluence: NONE (0/3)

Weekly candles, ~3 years. Yellow line: 10-week EMA. Dashed lines: Fibonacci retracement of the last 52-week swing. Green arrow: an active DR1 support reclaim (see Live signals above for when it fired).

Assumptions & data quality

Data source: yfinance
Growth (g1) source: min(revenueCAGR,cfCAGR)
Valuation model: DCF_OCF
Debt as % of DCF PV: 59.9%
Public economic interest: 98.5%

These are model outputs built on assumptions (growth rate, discount rate, margin of safety), not facts - trust but verify, especially for LOW cash-flow-reliability or UNKNOWN-quality rows.